

1/7


Changes in contrast-enhancing lesions:

FIG. 1

2/7





FIG. 2B

FIG. 2A

3/7



4/7




FIG. 4B

FIG. 4A

5/7




FIG. 5

Parallel to complete blockage of CD25 by Zenapax, also the proliferation of in-vivo activated T cells to IL-2 decreases




FIG. 6A

FIG. 6B

Upregulation of CTLA-4 on CD4+ T cells
during administration of Zenapax.




FIG. 7